Latest & greatest articles for levothyroxine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on levothyroxine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on levothyroxine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for levothyroxine

21. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature

The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

22. Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review

Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review Hrytsiuk I, Gilbert R, Logan S, Pindoria S, Brook C G Authors' objectives To determine the effect of levothyroxine sodium starting dose on cognitive development, growth or behaviour in children (...) of levothyroxine. Participants included in the review Children with congenital hypothyroidism, as identified by neonatal screening, whose global or cognitive development had been assessed using a population-standardised measure. The children included in the review were aged between 1 and 14 years. Outcomes assessed in the review First, the authors compared standardised doses of levothyroxine treatment with the mean standardised development scores in cohorts with different starting doses of levothyroxine

2002 DARE.

23. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. (Abstract)

Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. To compare relative bioavailability of Synthroid, Levoxine (Levoxine has been renamed Levoxyl), and 2 generic levothyroxine sodium preparations.Single-blind (primary investigators blinded), randomized, 4-way crossover trial.Ambulatory care.Twenty-two women with hypothyroidism who were clinically and chemically euthyroid and were receiving levothyroxine sodium, 0.1 or 0.15 mg.All patients received (...) each of the 4 levothyroxine products for 6-week periods in the same dosage as their prestudy regimen with no washout period. The order of the drug sequences was randomly determined before study initiation.Area under the curve, time to peak serum concentrations, and peak serum concentrations of thyroxine, triiodothyronine, and free thyroxine index for all 4 products.All data analyses were completed prior to unblinding of the product codes. No significant differences between the 4 products were found

1997 JAMA Controlled trial quality: uncertain

24. Effects of restricting levothyroxine dosage strength availability

Effects of restricting levothyroxine dosage strength availability Effects of restricting levothyroxine dosage strength availability Effects of restricting levothyroxine dosage strength availability Ain K B, Pucino F, Csako G, Wesley R A, Drass J A, Clark C, Ketteridge P, Crawford K, Banks S M, Dorworth T E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prescribing restricted versus nonrestricted dosage strength of levothyroxine to patients requiring thyroid hormone replacement or suppression of thyrotropin (TSH). The nonrestricted use of levothyroxine consisted of tablets containing 25, 50, 75, 100, 112, 125, 150, 175, 200, and 300 micrograms, while in the restricted-use, only five dosage strengths (25, 50, 100, 125, 150

1996 NHS Economic Evaluation Database.

25. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. (Abstract)

Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. Thyroid nodules are present in up to 50 percent of adults in the fifth decade of life. Patients are often treated with thyroxine in order to reduce the size of the nodule, but the efficacy of thyrotropin-suppressive therapy with thyroxine remains uncertain. In this study, 53 patients with a colloid solitary thyroid nodule confirmed by biopsy were randomly assigned in a double-blind (...) manner to receive placebo (n = 25) or levothyroxine (n = 28) for six months. Before treatment, pertechnetate-99m thyroid scanning showed that 22 percent of the nodules were functional, 25 percent hypofunctional, and 53 percent nonfunctional. High-resolution (10-MHz) sonography was used to measure the size of the nodules before and after treatment. Suppression of thyrotropin release was confirmed in the levothyroxine-treated group by the administration of thyrotropin-releasing hormone; thyrotropin

1987 NEJM Controlled trial quality: uncertain